The University of San Francisco, California, is running a clinical trial for Lactin-V, a possible new treatment for bacterial vaginosis that includes MetroGel and Lactobacillus crispatus. This product is designed to improve the three-month cure mark. The study is comparing the treatment to placebo.
Official study title is:
Phase II-b Randomized Double-Blind Placebo-Controlled Trial of Lactobacillus Crispatus CTV-05 (LACTIN-V) to Prevent the Recurrence of Bacterial Vaginosis
- Aged 18-45
- Capable of reading and writing English and voluntarily provide written informed consent to participate in the study and comply with all study procedures
- Untreated BV (asymptomatic or symptomatic) as diagnosed during the screening visit defined by>/=3 Amsel criteria AND confirmed in the laboratory using the Nugent scoring system (Nugent Score>/=4)